$0.21 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post $0.21 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for AngioDynamics’ earnings. AngioDynamics posted earnings per share of $0.19 during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.5%. The company is scheduled to announce its next earnings results on Tuesday, July 17th.

According to Zacks, analysts expect that AngioDynamics will report full-year earnings of $0.74 per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of $0.93 per share, with EPS estimates ranging from $0.90 to $0.95. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover AngioDynamics.

How to Become a New Pot Stock Millionaire

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The firm had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%.

A number of equities analysts have recently issued reports on the company. BidaskClub upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, March 30th. Zacks Investment Research downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. ValuEngine upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday. TheStreet downgraded AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity raised their price target on AngioDynamics from $16.50 to $17.00 and gave the stock a “hold” rating in a research note on Monday, April 2nd. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.87.

Shares of ANGO stock traded up $0.11 on Monday, reaching $18.99. The stock had a trading volume of 36,910 shares, compared to its average volume of 262,137. The company has a market cap of $694.87, a P/E ratio of 26.01, a price-to-earnings-growth ratio of 1.70 and a beta of 1.00. AngioDynamics has a 1 year low of $14.80 and a 1 year high of $19.25. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.88 and a quick ratio of 1.84.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fenimore Asset Management Inc. lifted its position in AngioDynamics by 0.6% during the fourth quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock valued at $9,886,000 after purchasing an additional 3,715 shares in the last quarter. First Trust Advisors LP lifted its position in AngioDynamics by 13.7% during the fourth quarter. First Trust Advisors LP now owns 32,866 shares of the medical instruments supplier’s stock valued at $547,000 after purchasing an additional 3,968 shares in the last quarter. Legal & General Group Plc lifted its position in AngioDynamics by 7.0% during the third quarter. Legal & General Group Plc now owns 65,557 shares of the medical instruments supplier’s stock valued at $1,119,000 after purchasing an additional 4,296 shares in the last quarter. Highbridge Capital Management LLC lifted its position in AngioDynamics by 21.4% during the third quarter. Highbridge Capital Management LLC now owns 25,304 shares of the medical instruments supplier’s stock valued at $432,000 after purchasing an additional 4,461 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in AngioDynamics by 50.9% during the third quarter. BNP Paribas Arbitrage SA now owns 21,329 shares of the medical instruments supplier’s stock valued at $365,000 after purchasing an additional 7,194 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.

WARNING: This story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3343867/0-21-earnings-per-share-expected-for-angiodynamics-inc-ango-this-quarter.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Omega Diagnostics Group  Insider Kieron Harbison Purchases 50,000 Shares of Stock
Omega Diagnostics Group Insider Kieron Harbison Purchases 50,000 Shares of Stock
Capita Plc  Insider Andrew Williams Acquires 30,000 Shares of Stock
Capita Plc Insider Andrew Williams Acquires 30,000 Shares of Stock
Vitamin Cottage Natural Grocers  Expected to Announce Quarterly Sales of $210.09 Million
Vitamin Cottage Natural Grocers Expected to Announce Quarterly Sales of $210.09 Million
Zacks: Brokerages Expect Rockwell Collins  Will Post Quarterly Sales of $2.14 Billion
Zacks: Brokerages Expect Rockwell Collins Will Post Quarterly Sales of $2.14 Billion
POA Network  1-Day Trading Volume Tops $10.15 Million
POA Network 1-Day Trading Volume Tops $10.15 Million
Digital Money Bits  Price Reaches $0.0029 on Top Exchanges
Digital Money Bits Price Reaches $0.0029 on Top Exchanges


© 2006-2018 Ticker Report. Google+.